Global Kidney/Renal Fibrosis Treatment Market Report By Type Therapeutics (Angiotensin II Receptor Blockers (ARBs), Angiotensin Converting Enzyme (ACE) Inhibitors, Pirfenidone, Renin Inhibitors, and Vasopeptidase Inhibitors), By Diagnostic Center (Hospital Testing, Commercial/Private Hospitals, Public Health Hospitals, Clinics, and Home Treatment) And By Regions - Industry Trends, Size, Share, Growth, Estimation and Forecast, 2017-2024
ID:VMR11210051
May 2018
Report Formats:

In the current scenario, the Kidney/Renal Fibrosis Treatment market is an extremely beneficial commercial segment due to the growing number of patients suffering from various types CKD and renal fibrosis. Moreover, increasing government support for developing novel therapies and rising investment in R&D on developing personalized medicine in various private and the public hospital is further propelling the market growth. The advent of the promising drug in the market coupled with the increasing medical expenditure and growing medical tourism rate is another major factor pushing the market growth uphill. Additionally, various recent technological breakthrough such as point-of-care drug delivery systems and penetration of personalized drug is likely to offer opportunity growth to the market over the forecast period.

As per Value Market Report, Kidney/Renal Fibrosis Market is expected to be worth USD 10,486.5 MN by 2024 with a CAGR of 3.5%.
 
ANGIOTENSIN-CONVERTING ENZYME (ACE) TO LEAD THE SEGMENT
It is estimated that ACE Inhibitors will touch USD 3,735.7 MN by end of 2024. The ACE inhibitor is dominating the segment owing to the rising application of a various disorder such as heart, blood vessel, and kidney problems. Basically, this group of drugs causes relaxation of blood vessels as well as a decrease in blood volume, which resulted in lower blood pressure and decreased oxygen demand from the heart. They curb the growth of angiotensin-converting enzyme, an important component of the renin-angiotensin system. Henceforth, this segment is likely to grow on the ground of rising prevalence of various renal disinfections along with the growing population base across the globe.
 
HOSPITAL TESTING TO GAIN THE TRACTION
The hospital testing is accounted for the largest market in 2017. The hospital testing is leading the segment owing to the growing investment in R&D on developing personalized medicine in various private and the public hospital. Also, the rising number of the hospital along with growing healthcare expenditure is another major factor in boosting the growth of the segment.
 
NORTH AMERICA EMERGED AS THE LARGEST MARKET FOR KIDNEY FIBROSIS
North America is accounted for the largest market for kidney fibrosis treatment owing to the presence of a large base of patients suffering from chronic kidney disease (CKD).  Major driving factors raising the growth of this market are the growing base of the population suffering from chronic kidney diseases and high incidence rate of renal fibrosis among the population. Moreover, the development of safe and effective therapeutics for the treatment of kidney fibrosis is contributing to the growth of the regional market.
 
THIS REPORT INCLUDES KEY PLAYERS ALONG WITH THEIR MARKET SHARE
Galectin Therapeutics, Merck & Co., F. Hoffman-La Roche Ltd., Pfizer Inc., InterMune Inc., ProMetic Life-Sciences Inc., La Jolla Pharmaceutical Company, Genzyme Corporation, and BioLine Rx Ltd

As per this study the global kidney/renal fibrosis treatment market was valued USD 8,320.5 MN (by revenue) in 2017 and is anticipated to reach USD 10,486.5 MN by 2024 with a CAGR of 3.5%.
 
Technically, fibrosis is a biological process which leads to the formation of access fibrous connective tissue in an organ/tissue in a repetitive way. Fibrosis can be a volatile, benign, or pathological state. In response to injury, this is called scarring, and if fibrosis rises from a single cell line, this is called a fibroma. Basically, it is related to the process of scarring. The process is initiated when immune cells such as macrophages release soluble factors that stimulate fibroblasts. Kidney/renal fibrosis may be caused due to disease/infection in the kidney.
 
Objectives of the Study:

  • Define and measure the global kidney/renal fibrosis treatment market
  • Revenue forecast of the global kidney/renal fibrosis treatment market and its various sub-segments with respect to main geographies
  • Analyze and identify major market trends along with the factors driving or inhibiting the market growth
  • Study the company profiles of the major market players with their market share
  • Analyze competitive developments
 
Market Dynamics
 
The kidney/renal fibrosis treatment market is a highly beneficial market owing to the increasing base of a population suffering from chronic kidney diseases and renal fibrosis. Moreover, increasing government support for developing novel therapies and rising investment in R&D on developing personalized medicine in various private and the public hospital is further propelling the market growth. On the flip side, strict regulatory approvals related to kidney fibrosis therapeutics may limit the market growth.
 
This detailed market study is centered on the data obtained from multiple sources and is analyzed using numerous tools including porter’s five forces analysis, market attractiveness analysis and value chain analysis. These tools are employed to gain insights of the potential value of the market facilitating the business strategists with the latest growth opportunities. Additionally, these tools also provide a detailed analysis of each application/product segment in the global market of kidney/renal fibrosis treatment.
 
Market Segmentation
 
The broad kidney/renal fibrosis treatment market has been sub-grouped into therapeutics, and diagnostic center. The report studies these subsets with respect to the geographical segmentation. The strategists can gain a detailed insight and devise appropriate strategies to target specific market. This detail will lead to a focused approach leading to identification of better opportunities.
 
By Diagnostic Center Market Share 2017
 
Kidney/Renal Fibrosis Treatment Market By Diagnostic Center
 
By Therapeutics
  • Angiotensin II Receptor Blockers (ARBs)
  • Angiotensin Converting Enzyme (ACE) Inhibitors
  • Pirfenidone
  • Renin Inhibitors
  • Vasopeptidase Inhibitors
 
By Diagnostic Center
  • Hospital Testing
  • Commercial/Private Hospitals
  • Public Health Hospitals
  • Clinics
  • Home Treatment
 
Regional Analysis
 
Furthermore, the report comprises of the geographical segmentation which mainly focuses on current and forecast demand for kidney/renal fibrosis treatment in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The report further focuses on demand for individual application segments in all the regions.
 
Europe Kidney/Renal Fibrosis Treatment Market By Revenue (USD MN)
 
Europe Kidney/Renal Fibrosis Treatment Market By Revenue
 
The report also covers detailed competitive landscape including company profiles of key players operating in the global market. The key players in the kidney/renal fibrosis treatment market includes Merck & Co., F. Hoffman-La Roche Ltd., Pfizer Inc., Galectin Therapeutics, La Jolla Pharmaceutical Company, InterMune Inc., ProMetic Life-Sciences Inc., Genzyme Corporation, and BioLine Rx Ltd. An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.
 
METHODOLOGY:
 
A combination of primary and secondary research has been used to determine the market estimates and forecasts. Sources used for secondary research include (but not limited to) Paid Data Sources, Company Websites, Technical Journals, Annual Reports, SEC Filings and various other industry publications. Specific details on methodology used for this report can be provided on demand. 

1. INTRODUCTION

  • Introduction To Kidney/Renal Fibrosis Treatment
  • Report Description
    • Objectives Of The Study
    • Assumptions
  • Research Scope
  • Research Methodology
    • Data Source
 
2. EXECUTIVE SUMMARY
  • Market Highlight
  • Global Kidney/Renal Fibrosis Treatment Market: Snapshot
 
3. MARKET ANALYSIS
  • Drivers
  • Restraints
  • Opportunities
  • Porter’s Five Forces Analysis
  • Value Chain Analysis
 
4. KIDNEY/RENAL FIBROSIS TREATMENT MARKET ANALYSIS BY THERAPEUTICS
  • Market In Angiotensin II Receptor Blockers (ARBs)
  • Market In Angiotensin Converting Enzyme (ACE) Inhibitors
  • Market In Pirfenidone
  • Market In Renin Inhibitors
  • Market In Vasopeptidase Inhibitors
 
5. KIDNEY/RENAL FIBROSIS TREATMENT MARKET ANALYSIS BY DIAGNOSTIC CENTER
  • Market In Hospital Testing
  • Market In Commercial/Private Hospitals
  • Market In Public Health Hospitals
  • Market In Clinics
  • Market In Home Treatment
 
6. KIDNEY/RENAL FIBROSIS TREATMENT MARKET ANALYSIS BY GEOGRAPHY
  • North America (NA)
    • North America Market Estimates
    • North America Market Estimates By Country
    • United States (U.S.) Market Estimates By Segments
    • Canada Market Estimates By Segments
    • Mexico Market Estimates By Segments
  • Europe (EU)
    • Europe Market Estimates
    • Europe Market Estimates By Country
    • United Kingdom (UK) Market Estimates By Segments
    • Germany Market Estimates By Segments
    • France Market Estimates By Segments
    • Rest Of Europe Market Estimates By Segments
  • Asia Pacific (APAC)
    • Asia Pacific Market Estimates
    • Asia Pacific Market Estimates By Country  
    • China Market Estimates By Segments
    • Japan Market Estimates By Segments
    • India Market Estimates By Segments
    • Rest Of Asia Pacific Market Estimates By Segments  
  • Latin America (LA)   
    • Latin America Market Estimates
    • Latin America Market Estimates By Country
    • Brazil Market Estimates By Segments
    • Rest Of Latin America Market Estimates By Segments
  • Middle East And Africa (MEA)   
    • Middle East And Africa Market Estimates
    • Middle East And Africa Market Estimates By Country
    • Middle East Market Estimates By Segments
    • Africa Market Estimates By Segments
 
7. COMPETITIVE LANDSCAPE OF THE KIDNEY/RENAL FIBROSIS TREATMENT COMPANIES
  • Market Competition
  • Partnerships/Collaborations/Agreements
  • Mergers And Acquisitions
  • New Product Launches
  • Other Developments
 
8. COMPANY PROFILES OF THE KIDNEY/RENAL FIBROSIS TREATMENT INDUSTRY (Company Overview, Financial, Major Products & Recent Development)
  • BioLine Rx Ltd.
  • F. Hoffman-La Roche Ltd.
  • Galectin Therapeutics
  • Genzyme Corporation
  • InterMune Inc.
  • La Jolla Pharmaceutical Company
  • Merck & Co.
  • Pfizer Inc.
  • ProMetic Life-Sciences Inc.
 
* Tentative TOC
 
 
LIST OF TABLES
 
Table 1.  Market Highlights Of Kidney/Renal Fibrosis Treatment
Table 2.  Global Kidney/Renal Fibrosis Treatment Market By Therapeutics
Table 3.  Global Kidney/Renal Fibrosis Treatment Market By Diagnostic Center
Table 4.  Global Kidney/Renal Fibrosis Treatment Market By Geography
Table 5.  North America Kidney/Renal Fibrosis Treatment Market
Table 6.  Europe Kidney/Renal Fibrosis Treatment Market
Table 7.  Asia Pacific Kidney/Renal Fibrosis Treatment Market
Table 8.  Latin America Kidney/Renal Fibrosis Treatment Market
Table 9.  Middle East And Africa Kidney/Renal Fibrosis Treatment Market 
Table 10. Partnership/Collaboration/Agreements
Table 11. Mergers And Acquisitions
Table 12. New Product Development
Table 13. Other Developments
 
  
LIST OF FIGURES
 
Fig. 1.     Market Segmentation Of Kidney/Renal Fibrosis Treatment Market 
Fig. 2.     Top-Down Approach   
Fig. 3.     Bottom-Up Approach   
Fig. 4.     Market Highlights Of Kidney/Renal Fibrosis Treatment
Fig. 5.     Value Chain Analysis
Fig. 6.     Porter’s Five Forces Analysis
Fig. 7.     Global Kidney/Renal Fibrosis Treatment Market By Therapeutics
Fig. 8.     Global Kidney/Renal Fibrosis Treatment Market By Diagnostic Center
Fig. 9.     Global Kidney/Renal Fibrosis Treatment Market By Geography
Fig. 10.   North America Kidney/Renal Fibrosis Treatment Market
Fig. 11.   Europe Kidney/Renal Fibrosis Treatment Market
Fig. 12.   Asia Pacific Kidney/Renal Fibrosis Treatment Market
Fig. 13.   Latin America Kidney/Renal Fibrosis Treatment Market
Fig. 14.   Middle East And Africa Kidney/Renal Fibrosis Treatment Market
Fig. 15.   Market Share Of Kidney/Renal Fibrosis Treatment Companies
Fig. 16.   Recent Developments In Kidney/Renal Fibrosis Treatment Industry
 
 
* Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

Client First Policy
Excellent Quality
Robust After Sales Support
24/7 Email Support

Clients

Testimonials